Summary
On October 27, 2026, Anthropic reported early progress using Claude to accelerate drug development: it has built deep research collaborations with six biotech partners including BigHat and Bristol Myers Squibb, acquired one-person startup Mithril Medicine, and its rare pediatric muscular atrophy program could enter human trials as early as late 2028.
Event Overview
- Date: Anthropic published a research article on October 27, 2026.
- Parties: Anthropic, and six biotech research partners — BigHat Biosciences, Bristol Myers Squibb, Divergence Labs, Enveda, Generate Biomedicines and The Column Group.
- Event: Per Anthropic's official research article, over the past months it formed deep research collaborations with six drug-discovery organizations, used Claude for drug design and regulatory-document work, acquired one-person company Mithril Medicine, and co-founded a new company, Pleiades, with TCG.
Key Information
| Item | Detail |
|---|---|
| Published | October 27, 2026 (Anthropic research article) |
| Partner count | Six: BigHat Biosciences, Bristol Myers Squibb, Divergence Labs, Enveda, Generate Biomedicines, The Column Group |
| Generate result | Claude Code redesigned a CAR-T genetic instruction ~70% shorter; receptor output by immune cells ~10x |
| Divergence result | ~35,000 antibody designs autonomously in ~1 month; 3 bind IgE and 20 detach it from immune cells in early tests |
| BigHat result | ~1,010 variants built and tested in ~10 weeks; best molecule >10x binding, +18°C thermal stability, >100x slower aggregation |
| Enveda result | Found all 11 human-review issues plus 7 more in a 1,061-page document; review cut from 25+ hours to under 3 hours (~-89%) |
| Regulatory draft | One regulatory-document draft took only 4 hours (human effort ~3 months) |
| In-house program | Acquired Mithril Medicine; a rare muscular-atrophy therapy reached positive mouse results in under 18 months; human trials as early as late 2028 |
| New company | Co-founded Pleiades with TCG |
Background and Impact
- CAR-T redesign: Per Anthropic, Generate Biomedicines used Claude Code to redesign a piece of genetic instruction for a CAR-T therapy; the new design is about 70% shorter, and lab tests showed immune cells produced about 10 times more receptors.
- Food-allergy antibodies: For food allergies, Divergence Labs had Claude autonomously generate about 35,000 antibody designs in roughly a month; early tests found 3 designs that bind IgE and 20 that detach it from immune cells.
- Protein engineering and regulatory docs: BigHat built and tested about 1,010 variants in about 10 weeks, with the best molecule showing more than 10-fold stronger binding, 18°C higher thermal stability and more than 100-fold slower aggregation. Enveda, in a 1,061-page document test, found all 11 issues human review found plus flagged 7 more; human review time dropped from 25-plus hours to under 3 hours (about -89%), and one regulatory-document draft took only 4 hours versus roughly 3 months by hand.
- In-house pipeline and acquisition: Anthropic said it acquired one-person company Mithril Medicine, whose founder used Claude to advance a rare muscular-atrophy therapy from idea to positive mouse results in under 18 months, with human clinical trials possible as early as late 2028; Anthropic also co-founded a new company, Pleiades, with TCG.